top of page

RCE Timeline

Since RCE started in 2018, we've been busy developing the technology  that we so strongly believe in. The timeline below presents some of the highlights over the last 6 years, and some of the upcoming things in the near future (at least some of the ones we can share publicly!). 

2024

  • Pre-hospital pilot in Resuscitated Cardiac Arrest Patients completed at University of Washington, presented at American College of Emergency Physicians 2024

  • Second and Third patents issued by the USPTO

  • 600 patients multi-site clinical across 10 hospitals completed

2023

  • Multi-site trial findings presented at American College of Cardiology - Late Breaking Clinical Trials, published in European Heart Journal

  • Multi-site clinical study in 840 patients conducted across 10 hospitals

  • Proteomics and advanced biochemical analysis of pre-clinical blood samples completed

  • Completed Cedars Sinai accelerator program 

  • First-in-human continuous monitoring in patients undergoing cath procedures completed at Cedars Sinai

  • RCE Wins the 2023 American Heart Association Health Technology Award

2022

  • First RCE patent issued by USPTO

  • Multisite study in 238 patients across 5 hospitals

  • Version 3 of infrared wearable developed

  • Infrasensor device developed

  • Initial version of Machine Learning algorithms for heart attack diagnostics are developed

  • Optical technology integration and continuous trending patents are filed

  • Poster presented at American Heart Association conference

​

​

2021

  • Second pilot study is completed at UCSF

  • Translation Research paper is published in Nature-Communications Medicine

  • First ever continuous trending data investigated in pre-clinical pilot study

2020

  • RCE begins first round of funding, among COVID slowdown challenges

  • Completed TMCx (Texas Medical Center) accelerator program 

  • Version 2 of the infrared wearable is developed

2019

  • First version of our non-invasive infrared wearable is developed and tested in initial pilot study

  • Biomarker quantificaion and disease phenotyping patents are filed

2018

  • RCE technologies is incorporated

  • Wet Lab studies are completed

  • Optical technology patents are filed

2020

  • RCE begins first round of funding, among COVID slowdown challenges

  • Completed TMCx (Texas Medical Center) accelerator program 

  • Version 2 of the infrared wearable is developed

2019

  • First version of our non-invasive infrared wearable is developed and tested in initial pilot study

  • Biomarker quantificaion and disease phenotyping patents are filed

2018

  • RCE technologies is incorporated

  • Wet Lab studies are completed

  • Optical technology patents are filed

2021

  • Second pilot study is completed at UCSF

  • Translation Research paper is published in Nature-Communications Medicine

  • First ever continuous trending data investigated in pre-clinical pilot study

2022

  • First RCE patent issued by USPTO

  • Multisite study in 238 patients across 5 hospitals

  • Version 3 of infrared wearable developed

  • Infrasensor device developed

  • Initial version of Machine Learning algorithms for heart attack diagnostics are developed

  • Optical technology integration and continuous trending patents are filed

  • Poster presented at American Heart Association conference

2023

  • Multi-site trial findings presented at American College of Cardiology - Late Breaking Clinical Trials, published in European Heart Journal

  • Multi-site clinical study in 840 patients conducted across 10 hospitals

  • Proteomics and advanced biochemical analysis of pre-clinical blood samples completed

  • Completed Cedars Sinai accelerator program 

  • First-in-human continuous monitoring in patients undergoing cath procedures completed at Cedars Sinai

  • RCE Wins the 2023 American Heart Association Health Technology Award

2024

  • Pre-hospital pilot in Resuscitated Cardiac Arrest Patients completed at University of Washington, presented at American College of Emergency Physicians 2024

  • Second and Third patents issued by the USPTO

  • 600 patients multi-site clinical across 10 hospitals completed

  • In 2025 we will launch a FDA pivotal trial for Emergency Departments, as well as Licensing and Pharmaceutical collaboration.

  • For 2026, we are planning the Market Launch for Emergency Departments and generation of evidence for Integrated Urgent Care and Ambulance Services.

And lots more coming soon!

bottom of page